Vineet Laboratories Ltd

Meeting Details

• Date: Tuesday, 25, 2026; time and venue not disclosed.

Key Agenda Items

• Approve Audited Standalone Financial Results for Q4 and FY ended March 31, 2026.

Other Notes

• Trading window closed for insiders until 48 hours after results declaration.

Issue Overview

• Type: Rights Issue; securities: Equity Shares.
• Total issue size and net proceeds disclosed; no undersubscription.
• Board approved revision in deployment plan due to project delays.
• Main objectives: debt repayment, capex for effluent plant, expansion, general corporate purposes.

Utilisation of Proceeds

• Utilisation is as per disclosures; no material deviations observed per MA.
• Delays in objects; deployment revision approved by the Board on 13 Aug 2026.
• Repayment of bank loans: fully utilised.
• Effluent treatment plant: utilised in quarter; some funds remain unutilised.
• Expansion of production facility: partial utilisation; sizeable unutilised balance; revision planned.
• General corporate purposes: utilised in quarter; board-approved allocations.
• Issue expenses: utilised; some proceeds inadvertently used outside objects; reversed August 2026.
• Unutilised proceeds currently parked in monitoring and HDFC/current accounts.

Governance and Compliance

• Approvals status: NA; MA notes no comments on approvals.
• Material events: board-approved revision; delays due to project scope finalisation.
• Board resolution approved deployment revision on August 13, 2026.
• Unutilised funds held in monitoring/account balances.

General Corporate Purpose (GCP)

• GCP: Not applicable; no separate GCP utilisation reported.

Board meeting deferment

• Board meeting to approve the audited financial results for FY2026 postponed; fresh date to be announced.
• Fresh notice with revised date/time/venue will be issued, per SEBI LODR requirements.

Meeting Details

• Board meeting scheduled for Wednesday, July 15, 2026.

Key Agenda Items

• Consider and approve Audited Standalone Financial Results for Q4 and FY ended March 31, 2026.

Other Notes

• Trading window remains closed for Designated Persons until 48 hours after results declaration.

🗓️ Meeting Details

• Board meeting scheduled for Saturday, February 14, 2026.

📊 Financial Performance

• Approval of unaudited standalone financial results for Q3 ended December 31, 2025.
• Consideration of Limited Review Report for Q3 financials.

Director Appointment

• Approved special resolution to appoint Ms. Jasmin Kunal Tailor (DIN: 10794164) as Independent Director of Vineet Laboratories Limited.
• Promoters voted 100% in favor with 99.85% voting turnout; public non-institutions voted 99.89% in favor.
• Overall approval was 99.9936% with 13.23% total voting turnout.
• No promoter interest or participation in the appointment.
• Board strengthened by addition of an Independent Director.
• No changes to shareholding, control, or capital structure.

Board Appointment

• Special resolution passed for appointment of Ms. Jasmin Kunal Tailor as Independent Director on February 7, 2026.
• Ms. Jasmin Kunal Tailor’s appointment was the sole agenda item for shareholder approval.

Meeting and Voting Details ️

• EGM held on February 7, 2026, via video conferencing, chaired by Managing Director Gaddam Venkata Ramana.
• Remote e-voting conducted from February 4 to 6, 2026, with additional voting post-meeting.
• Meeting attended by 51 members, including all key directors and management personnel.

Governance and Outcomes

• No changes reported to shareholding, control, capital structure, or remuneration.
• Voting outcome details and opposition were not disclosed.